| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
CEF8 targets the immune system, specifically HLA-B*2705-restricted cytotoxic T lymphocytes. As an HLA-B*2705-restricted epitope, it is recognized by CTLs in the context of HLA-B*2705 MHC class I molecules. The peptide is associated with escape from CTL-mediated immunity, as viruses can acquire mutations in or adjacent to CTL epitopes to evade immune surveillance.
|
|---|---|
| ln Vitro |
In vitro, CEF8 is used to study CTL-mediated immunity and viral escape mechanisms. The peptide is presented by HLA-B*2705 molecules on the surface of antigen-presenting cells and is recognized by specific CTLs. T-cell receptor interactions and CTL activation can be studied using this peptide in in vitro assays.
|
| ln Vivo |
In vivo activity of CEF8 has been studied in the context of influenza virus infection and CTL-mediated immune responses. Viruses can exploit the acquisition of mutations in or adjacent to CTL epitopes to evade immune surveillance by CTLs. The peptide is used to study immune escape mechanisms in influenza virus infection.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for CEF8 typically involve studying its binding to HLA-B*2705 MHC class I molecules. The peptide is incubated with purified HLA-B*2705 protein or cell lysates expressing HLA-B*2705, and binding affinity is assessed using peptide-MHC binding assays. Stabilization of peptide-MHC complexes can be measured using ELISA or flow cytometry-based methods.
|
| Cell Assay |
In vitro cell-based assays for CEF8 typically employ antigen-presenting cells expressing HLA-B*2705 and CTL lines or clones specific for the epitope. Cells are pulsed with the peptide and co-cultured with CTLs. CTL activation is assessed by measuring IFN-γ production via ELISPOT or intracellular cytokine staining, cytotoxicity by ⁵¹Cr release or other killing assays, and T-cell proliferation by CFSE dilution.
|
| Animal Protocol |
In vivo animal studies with CEF8 have been conducted in the context of influenza virus infection models. HLA-B*2705 transgenic mice or other appropriate models are infected with influenza virus, and CTL responses to the CEF8 epitope are assessed. Viral escape mutations in the epitope are identified by sequencing. However, specific study protocols are not detailed in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of CEF8 have not been characterized, as it is a research peptide rather than a therapeutic agent. As a peptide, it is likely to be rapidly degraded by peptidases. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
The toxicity profile of CEF8 has not been characterized. The peptide is a research-grade immunology tool and is not intended for therapeutic use. No specific toxicology data are available.
|
| References | |
| Additional Infomation |
CEF8, Influenza Virus NP 383-391 is a research-grade peptide used in immunology research to study CTL-mediated immunity and viral escape mechanisms. It is not an approved therapeutic drug and has no clinical trial history. The peptide is supplied with purity ≥99%. The sequence corresponds to residues 383-391 of the influenza A virus nucleoprotein.
|
| Molecular Formula |
C54H85N19O13
|
|---|---|
| Molecular Weight |
1208.37221026421
|
| Exact Mass |
1207.657
|
| CAS # |
142479-13-8
|
| PubChem CID |
6082079
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-6
|
| Hydrogen Bond Donor Count |
20
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
86
|
| Complexity |
2330
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N
|
| InChi Key |
RSAAOPBSIPAHOK-NHUGIYAUSA-N
|
| InChi Code |
InChI=1S/C54H85N19O13/c1-5-27(2)41(49(83)68-37(14-9-21-63-53(58)59)46(80)73-42(29(4)75)50(84)69-38(51(85)86)15-10-22-64-54(60)61)72-43(77)28(3)66-47(81)40(24-31-25-65-35-12-7-6-11-33(31)35)71-48(82)39(23-30-16-18-32(76)19-17-30)70-45(79)36(13-8-20-62-52(56)57)67-44(78)34(55)26-74/h6-7,11-12,16-19,25,27-29,34,36-42,65,74-76H,5,8-10,13-15,20-24,26,55H2,1-4H3,(H,66,81)(H,67,78)(H,68,83)(H,69,84)(H,70,79)(H,71,82)(H,72,77)(H,73,80)(H,85,86)(H4,56,57,62)(H4,58,59,63)(H4,60,61,64)/t27-,28-,29+,34-,36-,37-,38-,39-,40-,41-,42-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8276 mL | 4.1378 mL | 8.2756 mL | |
| 5 mM | 0.1655 mL | 0.8276 mL | 1.6551 mL | |
| 10 mM | 0.0828 mL | 0.4138 mL | 0.8276 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
